Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | RHOA | P61586 | 3/20 | 0.36 |
| ▸ | RHOC | P08134 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4280629 | 0.92 | CXCR3 (0.45) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL15353991 | 0.92 | CXCR3 (0.37) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL4279051 | 0.91 | CXCR3 (0.44) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL4273193 | 0.88 | CXCR3 (0.46) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL15353982 | 0.85 | CXCR3 (0.39) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL4283978 | 0.83 | CXCR3 (0.43) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL15353969 | 0.83 | CXCR3 (0.38) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL8374009 | 0.81 | CXCR3 (0.48) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL8371565 | 0.81 | SMN1; SMN2 (0.38) | NAMPTCXCR3EPHX2GAARHOA | |
| SCHEMBL15353967 | 0.80 | CXCR3 (0.48) | NAMPTCXCR3EPHX2GAARHOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | NAMPT 1401/4885CXCR3 3807/4885EPHX2 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.